Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Health ProductsUEEC +2.61% Debt-to-Equity is -0.49 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 706 Medical Devices & Instruments companies, United Health Products ranks worse than 141642.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for United Health Products's Debt-to-Equity or its related term are showing as below:
UEEC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.96 Med: -0.44 Max: 1.06
Current: -0.49
During the past 13 years, the highest Debt-to-Equity Ratio of United Health Products was 1.06. The lowest was -1.96. And the median was -0.44.
UEEC's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs UEEC: -0.49
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
United Health Products Debt-to-Equity Related Terms
United Health Products Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for United Health Products's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UEEC vs FEMY, BNGO, RGNT: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, United Health Products's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Health Products Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where United Health Products's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Health Products (UEEC) has a Debt-to-Equity of -0.49 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on United Health Products and its competitors. According to the industry distribution chart, United Health Products ranks #999999 out of 706 companies in the Medical Devices & Instruments industry.
Is United Health Products' Debt-to-Equity too high?
United Health Products' current Debt-to-Equity is -0.49. Based on the distribution chart, United Health Products ranks #999999 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does United Health Products' Debt-to-Equity compare to FEMY and BNGO?
According to the Medical Devices & Instruments industry distribution chart, United Health Products ranks #999999 out of 706 companies for Debt-to-Equity. This places United Health Products in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on United Health Products and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Health Products's current Debt-to-Equity is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Health Products stock overvalued right now?
United Health Products (UEEC) has a current Debt-to-Equity of -0.49. The current Debt-to-Equity is -0.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For United Health Products (UEEC), the current Debt-to-Equity is -0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
United Health Products Inc develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Its gauze product, CelluSTAT, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The company are in the process of seeking regulatory approval to sells hemostatic gauze product line into the U.S. Class III and European CE Mark human surgical markets. The company operates as a single operating segment, focusing on the development and commercialization of medical devices, particularly its patented hemostatic gauze, CelluSTAT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UEEC has been successfully added to your 
